Adalimumab and Anti-Adalimumab antibody
Adalimumab and Anti-Adalimumab antibody-13581
Anti-TNF-alpha Drug
Adalimumab and Anti-Adalimumab antibody, DoseASSURE ADL
Humira
This test provides adalimumab drug concentration levels as well as the level of antiadalimumab antibodies. This test also includes serial monitoring
Monitor antiadalimumab therapy for individuals with Crohn's disease, inflammatory bowel disease, ulcerative colitis, rheumatoid arthritis, or other autoimmune conditions
Submission of the minimum volume does not allow for repeat testing
Immediatley following collection, mix sample by gently inverting 5 times
- Allow a minimum clotting time of 30-60 minutes
- Spin within two (2) hours of sample collection
Gold serum separator (SST) tube
- Allow sample to clot
- Spin within two (2) hours of sample collection
- Transfer serum to a Transfer vial/tube with cap - 12mL (LabCorp) labelled as "serum"
Refrigerated (preferred) - 7 days
Ambient - 7 days
Frozen - 308 days
- Plasma specimen received
Electrochemiluminescence Immunoassay (ECLIA)
Adalimumab drug level:
Quantitation limit: <0.6 μg/mL
Results ≥0.6 μg/mL indicate detection of adalimumab.
In the presence of antiadalimumab antibody, the adalimumab drug level reflects the antibody-unbound fraction of adalimumab concentration in serum.
Antiadalimumab antibody:
Quantitation limit: <25 ng/mL
Results ≥25 ng/mL indicate detection of adalimumab antibody
Low titer: 25-100 ng/mL
Intermediate titer: 101-300 ng/mL
Hight titer: ≥301 ng/mL
80145